Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panzem NCD in recurrent/resistant epithelial ovarian cancer
NCT00400348Phase 2Completed
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Oct 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 2-methoxyestradiol in epithelial ovarian cancer (EOC), primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC), sponsored by CASI Pharmaceuticals, Inc.. Started Oct 2006; status: completed.
02
Drugs
2-methoxyestradiol
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00400348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400348.